P/B
—
Surrozen
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
$206.9M
Market Cap • 9/22/2026
2015
(11 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
18
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
206,9M
EV
111,1M
EV/Revenue
9,7
EV/EBITDA
-2,5
EV/EBIT
-2,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-22,5%
Total Yield
-22,5%
Payout
0%
Retained Earnings
-604,6M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
300,4%
Capex/Revenue
1,9%
Capex/D&A
100%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
4,8%
% Goodwill
0%
ROE
265%
ROIC
—
Growth
CAGR Op. Income 5Y
-0,4%
CAGR Net Income 5Y
38,2%
CAGR EPS 5Y
9,5%
CAGR OCF 5Y
-2,8%
Leverage
N.D./EBITDA
2,2
Debt/Equity
0%
Current Ratio
12,1
Quick Ratio
11,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!